Similar articles

• Distribution of pomalidomide into semen of healthy male subjects after multiple doses.

  Li Y, Wang X, Liu L, Reyes J, Palmisano M, Zhou S. Li Y, et al. Clin Pharmacol. 2018 May 7;10:53-62. doi: 10.2147/CPAA.S167017. eCollection 2018. Clin Pharmacol. 2018. PMID: 29765255 Free PMC article.
• 2,4,6-Triamino-1,3,5-triazine-1H-isoindole-1,3(2H)-dione (1/3).

  Perpétuo GJ, Janczak J. Perpétuo GJ, et al. Acta Crystallogr C. 2007 May;63(Pt 5):o301-2. doi: 10.1107/S0108270107015880. Epub 2007 Apr 21. Acta Crystallogr C. 2007. PMID: 17478917
• Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.

  Hoy SM. Hoy SM. Drugs. 2017 Nov;77(17):1897-1908. doi: 10.1007/s40265-017-0833-y. Drugs. 2017. PMID: 29110190 Review.
• Pomalidomide: a review of its use in patients with recurrent multiple myeloma.

  Scott LJ. Scott LJ. Drugs. 2014 Apr;74(5):549-62. doi: 10.1007/s40265-014-0196-6. Drugs. 2014. PMID: 24590685 Review.
• The Synthesis, Anticancer Activity, Structure-Activity Relationships and Molecular Modelling Studies of Novel Isoindole-1,3(2H)-dione Compounds Containing Different Functional Groups.

  Tan A, Kizilkaya S, Kelestemur U, Akdemir A, Kara Y. Tan A, et al. Anticancer Agents Med Chem. 2020;20(11):1368-1378. doi: 10.2174/1871520620666200410080648. Anticancer Agents Med Chem. 2020. PMID: 32275494